Neurocrine Biosciences | NBIX - Ebit



金融业
股票价格
USD 169.40
资产
USD 5.63B
现金及等价物
USD 641.5M
销售成本
USD 61.6M
流动资产
USD 2.01B
流动负债
USD 984.6M
债务
USD 392.3M
EBIT
USD 343M
EBITDA
USD 375.3M
员工
1.8K
EPS每股收益
USD 3.29
股本和储备
USD 3.88B
销售毛利
USD 1.06B
债务利息支出
USD 300K
贷款资金
USD 169.5M
市值
USD 16.86B
净收入
USD 206.5M
营业费用
USD 779.7M
营业利润
USD 343M
普通股股本
USD 101.3M
PE价格收益
83.17
税前利润
USD 283.7M
销售收入
USD 1.12B
销售和管理费用
USD 366.3M
股票
USD 66.1M
贸易债权人
USD 754.1M
应收帐款人
USD 957.3M


Ebit 更改 日
AbbVie USD 6.88B 156M 2026-09
Acadia Pharmaceuticals USD 71.72M 33.88M 2026-09
Agios Pharmaceuticals USD -110.55M 527K 2026-06
ALKERMES USD 36.59M 102.52M 2026-09
Alnylam Pharmaceuticals USD 179.66M 67.06M 2026-09
Amgen USD 4.68B 65M 2026-09
Biogen USD 419.5M 663.3M 2026-09
BioMarin Pharmaceutical USD 205.6M 100M 2026-09
Cytokinetics USD -167.09M 12.08M 2026-09
Enanta Pharmaceuticals USD -23.54M 6.31M 2024-12
Exelixis USD 268.42M 20.01M 2026-09
Gilead Sciences USD 3.85B 1.17B 2026-06
Halozyme Therapeutics USD -60.68M 3.04M 2026-09
Incyte USD -707.47M 1.41B 2026-09
Ionis Pharmaceuticals USD -130M 27.71M 2026-09
Nektar Therapeutics USD -38.26M 19.17M 2026-03
Neurocrine Biosciences USD 343M 123.1M 2026-09
Pfizer USD 4.85B 5.03B 2026-09
Prothena USD -18.69M 44.48M 2026-06
Regeneron Pharmaceuticals USD 1.42B 675.7M 2026-06
Repligen USD 24.31M 3.18M 2026-09
Rigel Pharmaceuticals USD 447K 1.52M 2024-06
Sarepta Therapeutics USD -9.04M 22.33M 2026-09
Teva Pharmaceutical Industries USD 1.19B 954M 2026-09
Ultragenyx Pharmaceutical USD -110M 35M 2026-09
Vertex Pharmaceuticals USD 1.26B 11.3M 2026-09